Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Joint ( (JYNT) ) just unveiled an update.
The Joint Corp. reported a 2% revenue increase to $30.2 million for Q3 2024, despite a net loss of $3.2 million. The company continues its strategic refranchising efforts, resulting in a total of 963 clinics. CEO Sanjiv Razdan emphasized the company’s focus on growth, refranchising, and enhancing clinic economics to boost profitability and shareholder value. The company adjusted its 2024 guidance due to consumer headwinds, with expected system-wide sales between $525 million and $535 million.
See more insights into JYNT stock on TipRanks’ Stock Analysis page.
